NorthWest Biotherapeutics Inc (NWBO)

[ilovetech]

Danish - Great post. I found this point to be the least commonly raised, and IMHO to be a another hidden gem to watch out for.

This is a major shift.
• ORR (Objective Response Rate) endpoints can show clear tumor regression quickly, making trials faster, cheaper, and more appealing to regulators and partners.
• It’s also easier for market access (e.g., conditional approvals or accelerated pathways)

It's a loaded value proposition for any license, partnership, or BO discussions!